by The global neoantigens market is on the brink of substantial growth, driven by the escalating prevalence of cancers and other chronic diseases worldwide. Recent data reveals that cancer has overtaken heart disease as the leading cause of death across the globe. According to the World Health Organization (WHO), cancer was the primary cause of death in individuals under 70 years old in 183 countries in 2020, with an alarming 27.5 million new cancer diagnoses expected by 2040, leading to 163 million deaths, as per the International Agency for Research on Cancer (IARC).
The neoantigens market is anticipated to receive a significant boost in the coming years as factors such as lifestyle changes, inadequate physical activity, smoking, and shifting health and climatic conditions contribute to the surging global cancer incidence. This mounting cancer burden has placed immense pressure on healthcare systems worldwide, necessitating a focus on improved cancer treatment and prevention strategies.
In response to this global health crisis, the World Health Assembly adopted Resolution Cancer (WHA70.12) in 2017, calling for an integrated approach to cancer prevention and control. Governments and private organizations have joined forces to combat the growing cancer burden, creating a demand for more effective cancer preventive methods. As cancer cases continue to rise, there will be a growing need for innovative therapeutic approaches, driving the expansion of the neoantigens market.
The Promise of Neoantigens in Cancer Immunotherapy
Neoantigens, also known as tumor-specific antigens (TSAs), represent a repertoire of peptides that emerge from DNA mutations in tumor cells. Unlike other common tumor antigens, neoantigens are entirely absent from normal human organs or tissues. Targeting neoantigens holds the potential to enable the patients immune system to specifically identify and attack cancer cells without harming healthy ones, making them a promising avenue for cancer immunotherapy.
Rapid Growth in Combination Therapy
Combination therapy is poised to be the fastest-growing segment in the neoantigens market. The proliferation of clinical trials involving neoantigens in combination with immune checkpoint inhibitors (ICIs) and other cancer medications is expected to fuel this market expansion. Numerous companies have initiated clinical studies to explore neoantigens in combination therapy, such as Gritstone Oncology, Inc., which has partnered with Bristol-Myers Squibb Company for groundbreaking research.
North America Leads the Way
North America stands as the largest consumer of neoantigens and is projected to experience the highest growth rate in the neoantigens market. The United States, Canada, and Mexico collectively form the largest market for neoantigens, driven by increasing clinical studies, advancements in cancer immunotherapies, and government funding. With a rising number of cancer cases and a growing demand for sophisticated treatment strategies, North America is expected to dominate the neoantigens market.
A Bright Future for Neoantigens
The rising prevalence of cancer, the expanding number of clinical studies, and breakthroughs in cancer therapies are driving the global neoantigens market forward. As biotechnology continues to advance, the integration of neoantigens into cancer treatment strategies is becoming increasingly important. Neoantigens offer the potential to revolutionize cancer therapy by allowing for precise targeting of cancer cells, leading to improved patient outcomes.
Key players in the neoantigens market include Achilles Therapeutics plc, Cellesce Ltd, Frame Cancer Therapeutics, Genocea, Gradalis, Inc., Medigene AG, Immunicum AB, Ziopharm Oncology, Inc, Gritstone Oncology, Moderna, Inc, and Advaxis, Inc.
Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) https://www.fairfieldmarketresearch.com/report/neoantigens-market
Our Blogs:
http://www.pml4all.org/profiles/blogs/global-shisha-market-soars-with-a-promising-6-cagr-expected-to
About Us
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of
services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.
Contact
Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
Web: https://www.fairfieldmarketresearch.com/
Email: sales@fairfieldmarketresearch.com
This press release first seen on Brilad
COMTEX_441974894/2840/2023-10-16T11:41:14
Julian Lopez is professor emeritus of finance, served as the founding academic affairs dean and founding chair of the finance department.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No journalist was involved in the writing and production of this article.